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Abstract
Lymphatic filariasis (or elephantiasis) is a major neglected disease with an
estimated 120 million individuals infected and approximately 1.5 billion at risk in
endemic regions. It is a highly disfiguring and debilitating disease and one o f the major
causes o f global morbidity. Treatment options for this disease are few and new drug
targets and therapies need to be identified. We have identified a protein kinase ortholog
of human p38 mitogen-activated protein kinase (p38) expressed in the filarial parasite,

Brugia malayi (B. malayi), one of three causative agent o f lymphatic filariasis. We
hypothesize that this protein kinase, BmM PKl, is important for the organism’s growth
and viability and as such, may be a novel therapeutic target. Human p38 plays an
essential role in responses to stress, such as toxins, infection and inflammation as well as
cell cycle control and apoptosis. An ortholog found in the nematode, Caenorhabditis

elegans (C. elegans, PMK-1/2), plays a similar role in protecting the organism from
oxidative stress. Elimination of PMK-1/2 through genetic means results in the inability of
C. elegans to respond to oxidative stress, disrupts neuronal development, and innate
immune responses. Based on these and other observations we hypothesize that BmMPKl
plays a similar role in protecting B. malayi from oxidative stress and in parasite growth
and development.
The goals of this thesis project were: to produce recombinant BmMPKl kinase,
assess the effects of known inhibitors of human p38 against BmM PKl, assess the effects
of p38 inhibitors on B. malayi growth, replication, and response to oxidative stress.
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Introduction
Lymphatic fllariasis
Lymphatic fllariasis, also known as elephantiasis, is a highly disfiguring and
debilitating disease leading to permanent and long term disability. It affects more than
120 million people in 80 countries worldwide and is found in tropical and sub-tropical
climates (7). It is caused by thread-like parasitic worms, Wuchereria bancrofti (W.

bancrofti), Brugia malayi (B. malayi) and Brugia timori (B. timori). In 120 million
people affected by this disease, 90% of the cases are caused by W. bancrofti and 10% by

B. malayi and B. timori. The B. malayi is morphologically smaller in size than W.
bancrofti. The infection is transmitted by mosquitoes. Culex, Anopheles, Mansonia, and
Aedes vectors transmit W. bancrofti while Mansonia and Aedes vectors transmit B.
%.

malayi. The infection is established when a mosquito takes a blood meal and introduces
the infective larvae (L3) to the human. The infective larvae migrate to the lymphatic
system and mature into adult worms that can live for 10-15 years. In the lymphatic
system, the adult worms mate and the female worms produce millions o f sheathed
microfilariae which enter the blood stream where they can survive for up to a year. The
microfilariae are subsequently ingested by a mosquito during a blood meal. The
microfilariae lose their sheaths and develop into infective L3 larvae inside the mosquito
and the cycle continues (Figure 1).

Lymphatic fllariasis is a major neglected disease and the World Health
Organization (WHO) along with other international agencies has formed a Global
Programme to Eliminate Lymphatic Filariasis (GPELF) to eradicate this disease by the
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year 2020. Presently, the treatment options for this disease are by the drug albendazole
alone or in combination with diethylcarbamazine (DEC) and Mectizan® (ivermectin) (7).
The treatments are effective against microfilariae but do not reliably kill adult worms (2).
Further research is needed to find more treatment options that eliminate the microfilariae
and kill the adult worms. A strategy to identify a potential drug target would be to
investigate parasitic-specific targets involved in the survival o f the organism. The
genome of B. malayi has been sequenced providing information on parasite targets useful
for developing new drugs (3). One class o f targets identified was parasitic protein
kinases. Kinases are involved in receptor mediated cell signaling pathways, and regulate
proliferation, apoptosis and anti-stress response. Protein kinases have been targeted for
drug development in a variety of protozoal and helminthic parasites (4). In addition,
protein kinases have been targeted for treating a variety of diseases such as inflammation
and cancer (4). The drug GLEEVEC®, an inhibitor o f the Bcr/Abl protein kinase, was the
first successful “targeted” cancer therapy for chronic myelogenous leukemia (CML).

Mitogen Activatedp38 kinase Family
One important class of protein kinase is the mitogen-activated protein kinases
(MAPK). MAPK are kinases that are involved in signaling pathways that respond to wide
variety o f extracellular stimuli such as mitogens, osmotic stress, heat shock and
inflammatory cytokines (5). MAPK regulate cellular activities such as gene expression,
mitosis, differentiation, proliferation, and cell survival/apoptosis. There are three family
members of MAPKs: The extracellular signal-regulated kinase (ERKs), c-Jun N-terminal
kinase/stress activated proteins (JNKs), and the p38 mitogen-activated stress kinases
2

(p38) (5). The ERK pathway is stimulated by growth factors while the JNK and p38
pathway are largely stimulated by stress such as ultraviolet light, heat shock, osmotic
shock, lipopolysaccharide (LPS), and pro-inflammatory cytokines.

The p38 pathway has been extensively studied as a potential therapeutic target in
humans for treating inflammatory disease (e.g. rheumatoid arthritis) with selective
inhibitors advancing into clinical trials (6). In addition to its role in the inflammatory
process, p38 has been shown to play important role in cell-cycle regulation, cell death,
development, differentiation, senescence and tumorigenesis (6). There are four different
isoforms of p38: p38-a (MAPK14), p38-P (MAPK11), p38-y (MAPK12 or ERK6) and
p38-Ô (MAPK13 or SAPK4). All isoforms o f p38 are activated by the upstream kinases
MAP kinase kinase 3 (MKK3) and MKK6 ( 6, 7) with exception o f p38-(3 which cannot
be activated by MKK3. p38 is activated by MKK3/6 through dual phosphorylation at
threonine and tyrosine in the T-G-Y m otif located within the regulatory loop between
subdomains VII and VIII. Activation o f p38 leads to the phosphorylation and activation
of a variety o f protein kinases (e.g. MK2) and transcription factors ( 6).•
A large variety of p38 inhibitors have been synthesized and as mentioned above,
some have advanced in clinical trials. p38 inhibitors fall into two distinct mechanism
classes, competitive with ATP and allosteric ( 6). The first p38 inhibitor developed was
SB203580, a pyridinylimidazole (8, 9). SB203580, RWJ67657, and other 2,4,5-triaryl
imadazoles are ATP competitive inhibitors that bind to both active and inactive forms of
the enzyme. These inhibitors bind only to the p38a and p38|3 isoforms and exhibit
submicromolar inhibitory (8, 9, 10). The allosteric class o f p38 inhibitors, best
exemplified by the compound BIRB796, potently inhibits all p38 isoforms (11). The
3

BIRB796 class of inhibitors bind to specific conformation of p38 called “DRG-out” (10).
BIRB796 exhibits a slow on-rate o f binding and a slow off-rate leading to picomolar
affinity for p38 and low nanomolar kinase inhibitory activity.

Structures for

representative p38 inhibitors are illustrated in Figure 2.

Parasitic Orthologs o f Human p38
MAPK orthologs have been identified in protozoal and helminthic parasites. In
one case, for the parasite

Toxoplasma gondii (T. gondii, causative agent of

toxoplasmosis), p38 inhibitors have been shown to inhibit the activity o f a MAPK
ortholog found in this parasite, tgmapk-1. These inhibitors inhibit proliferation o f the
parasite in vitro and treat lethal infection in a murine model o f toxoplasmosis (4). Recent
studies have shown that EmMPK2, an Echinococcus multicularis (E. multicularis, the
causative agent of alveolar echinococcosis, considered to be the most lethal helminthic
infection in humans). p38 inhibitors have shown to inhibit the activity o f an p38 MAPK
ortholog, EmMPK2, and has also been shown to kill E. multicularis in vitro (12).
A blast search of the Uniprot Protein Database (The European Bioinfomatics
Institute, EMBL-EBI, and the European Molecular Biology Laboratory, EMBL) using
the sequence for human p38 revealed a novel p38 ortholog from the filarial parasite B.

malayi exhibiting high homology (80%) to human p38, E. multicularis EmMPK2 and
Caenorhabditis elegans (C. elegans) PMK-1/2. A Clustal W comparison o f these
sequences is shown in Figure 3. The TGY dual phosphorylation site, M allosteric site,
and DFG activation loop located in the VII domain are highly conserved.

4

In view of the evolutionary conserved importance o f the p38 pathway, previous
reports of the detrimental effects of p38 inhibitors on T. gondii, and E. multiculararis
viability, my thesis goal were: to produce recombinant BmMPKl kinase, assess
inhibition by known p38 inhibitors, and to determine the effects p38 inhibitors on B.

malay i parasites.
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Materials and Methods
Generation o f pENTR221 containing BmMPKl
The full length BmMPKl sequence was obtained from the UniProt protein
database (The European Bioinfomatics Institute, EMBL-EBI, and the European
Molecular Biology Laboratory, EMBL). The Human codon optimized BmMPKl gene
was produced synthetically (Blue Heron Biotechnology, Bothell, WA) and cloned into
the Gateway system pENTR™221 entry vector (Invitrogen) (13, 14). The Invitrogen
Gateway technology is a cloning technology which allows efficient transfer o f DNA
sequences into multiple vectors making use o f the site-specific recombination properties
of bacteriophage lambda (14). The BmMPKl sequence is flanked by specific sites (att)
that are recognized by lambda recombinase. The pENTR™221 (entry clone) was
provided as a bacterial stab containi ng the BmMPKl gene flanked by attLl and attL2
sites and a kanamycin resistant gene.

The bacterial stab was pierced using a sterile wire loop and streaked
discontinuously onto a kanamycin agar plate (15). The agar plate was prepared by
dissolving

Luria-Bertani

(LB)

Agar

(Invitrogen)

with

distilled

water

as

per

manufacturer’s instructions (Invitrogen). The LB Agar was autoclaved and 50 pg/mL
kanamycin was added. It was poured into a 10 mm Petri dish and allowed to solidify.
After the plate solidified, it was placed in a 37°C incubator overnight. Then, the plates
were stored at 4°C until use.

The streaked plates were inoculated overnight and a single, well isolated, colony
was picked and inoculated into 10 mL o f LB Broth. LB broth was prepared by dissolving
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LB Broth (Invitrogen) in distilled water as per manufacturer’s instructions (Invitrogen).
LB broth was autoclaved and 50 pg/mL kanamycin was added. LB Broth containing the
colony was placed in a 37°C incubator with aeration shaking at 200 rpm for 16 hours.
After 16 hours, plasmid was prepared using the Pure Yield™ Plasmid Miniprep System
(Promega) as per manufacturer’s instructions. Prior to the plasmid miniprep, 6 mL of
bacterial glycerol stock was prepared in LB Broth containing 15% glycerol. The glycerol
stock was immediately placed in liquid nitrogen to freeze down the cells and stored at 80°C for future use. The purified pENTR™221 entry clone plasmid was stored at -20°C
for future use.

In order to determine the concentration o f the pENTR™221 entry clone from the
plasmid miniprep, a Hoechst 33258 dye DNA assay was performed (16). This assay is a
fluorescent based assay where the Hoechst dye intercalates between the adenine-thymine
base pairs of the DNA. In order to conduct the Hoechst DNA assay, the following stock
solutions were used: 10X Tris-NaCl-EDTA (TNE), 10X phosphate buffered saline (PBS
without calcium and magnesium), Hoechst Dye at 1 mg/mL diluted to 100X Hoechst dye
at 20 ug/mL, and calf thymus DNA 0.1 mg/mL. The 10X TNE solutions contain the
following: 0.1 M Tris, 2.0 M NaCl, and 0.01 M disodium ethylenediaminetetraacetic acid
(EDTA) which was adjusted to pH 7.4 with HC1. The working solution for the assay was
IX. The Hoechst dye was diluted to working concentration o f 300 ng/mL. The assay
volume was 200 pL with the standard calf thymus DNA and the entry clone diluted in IX
TNE. A 1600 ng/mL working solution o f calf thymus DNA was prepared and a standard
concentration curve from 12.5-800 ng/mL. The assay was conducted in a black 96-well
plate (Coming) by adding equal volumes o f the DNA (standard and entry clone) and
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Hoechst dye. The plate was read using Synergy 2 microplate reader using an excitation
wavelength of 360 nm and an emission wavelength o f 460 nm. The data was analyzed
using linear regression in Microsoft Office Excel 2007 (Microsoft) and we obtained 410
pg/mL ofpENTR™ 221.

Generation o f pDEST expression vectors containing BmMPKl
To generate an expression clones, the BmMPKl gene present in pENTR™221
was transferred to a variety of pDEST expression vector using in vitro LR recombination
reaction (Invitrogen). The pDEST vectors are expression vectors that contain a ccdB
selection marker and a chloramphenicol resistance gene that is flanked by attR.1 and

attR2 sites (77). The pDEST expression vectors also contain ampicillin and neomycin
resistance genes as positive selection markers. As stated earlier, pENTR™221 entry
clone contains the BmMPKl sequence which is flanked by attLl and attL2 sites. During
the recombination reaction, the LR clonase™ enzyme (Invitrogen) recognizes and binds
to the att sites located on the entry clone and the destination vector. The enzyme cleaves
the sites, promotes the exchange of the BmMPKl and ccdB sequence and covalently
ligates the DNA ends (14, 18). The net result is an expression clone with the BmMPKl
gene flanked by attBX and attB2 sites containing ampicillin and neomycin resistance
genes.

The decision was made to utilize a mammalian expression system for BmMPKl
production in order to take advantage o f the possibility o f activating BmMPKl by
inducing mammalian upstream kinases by stress (sodium arsenate treatment, 5) during
expression. Two mammalian pDEST expression vectors (Invitrogen) were generated,
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pDEST™27 and pDEST™26. pDEST™27 is N-terminal Glutathione S-transferase(GST)
fusion vector that generates a N-terminal GST tagged protein while pDEST™26
generates a N-terminal polyhistidine (6xHis) tagged protein. Both GST and His tags are
located upstream from the start codon in the pDEST™27 and pDEST™26 vectors
respectively. The focus here will be only on pDEST™27 since I did not observe
successful expression of His tagged BmMPKl in mammalian cells.

The destination vector were propagated using One Shot ccdB survival T1R
chemically competent Escherichia coli (E.coli) cells (Invitrogen) using the Heat shock
transformation technique. The One Shot ccdB survival T1R cells are resistant to ccdB
effects. The One Shot survival ccdB competent cells were thawed on ice and 1 pL o f the
vector were added to the cells. The cells with the vector were placed on ice for 10
minutes and heat shocked in 42°C water bath for 45-50 seconds. The cells were returned
back on ice for 2 minutes and 300 pL o f super optimal broth with catabolite repression
(SOC) was added. The cultures were placed in 37°C incubator with aeration shaking at
200 rpm for 60 minutes. After the one hour incubation, 50 pL o f transformed mixtures
were plated into pre-warmed LB agar plate containing 100 pg/mL ampicillin and 30
pg/mL chloramphenicol. These plates were placed in 37°C incubator and inoculated the
next day. The Pure Yield™ Plasmid Midiprep System was performed and glycerol stocks
of the destination vectors were made. The Hoechst DNA assay was performed to
determine the concentration of the plasmid as stated earlier and the expression vectors
were stored at -20°C for future use. We obtained 134 pg/mL o f pDEST™27.
Mammalian expression clones were prepared as per manufacturer’s instructions
(Invitrogen). To create the expression clones, the following components were used: 100
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ng of entry clone and 150 ng of the destination vector in a final volume o f 8 pL with TE
Buffer (10 mM tris HCL, pH 8.0, and 1 mM EDTA). The LR clonase™ enzyme was
thawed on ice for 2 minutes and vortexed for 2 seconds. Then, 2 pL o f LR clonase™
enzyme was added and incubated at 25°C for 2 hours. After the incubation, 1 pL of
Proteinase K solution (Invitrogen) was added to recombination mixture and incubated at
37°C for 10 minutes.

The recombination mixture was transformed into Library One Shot® Library
Efficiency DH5a Chemically Competent E. coli (Invitrogen) by adding 1 pL of
recombination mixture into 50 pL o f DH5a competent cells. The recombination mixture
was placed on ice for 30 minutes. After 30 minutes, the cells were heat-shocked for 30
seconds at 42°C water bath and immediately placed on ice where 450 pL o f SOC
medium was added at room temperature. The DH5a competent cells containing the
recombination mixtures were sealed and placed in a 37°C incubator on a shaker at 200
rpm for 60 minutes. After the one hour incubation, 100 pL o f transformed mixture was
plated onto pre-warmed LB agar plate containing 100 pg/mL carbenicillin and incubated
overnight at 37°C. Carbenicillin was used instead o f ampicillin since it was a stable form
of ampicillin and was a positive selection for the expression clone. The ccdB gene was
used as a negative selection since the gene expresses an inhibitor o f DH5a cells (14, 18).

After the overnight incubation, two single well isolated colonies from plates
containing mammalian expression vectors, BmMPKl/pDEST™ 27, were inoculated into
50 mL of LB Broth containing 100 pg/mL carbenicillin. The LB Broth was placed in a
37°C incubator with aeration shaking at 200 rpm for 16 hours. After 16 hours, Pure
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Yield™ Plasmid Midiprep System (Promega) was used for the purification o f the
mammalian expression vectors as per manufacturer’s instructions. Prior to the plasmid
extraction, 1 mL of glycerol stock was prepared for the mammalian vectors in LB Broth
containing 15% glycerol. The Hoechst DNA assay was performed as stated previously to
determine the plasmid concentration and the expression vectors were stored at -20°C for
future use. We obtained 236 pg/mL o f BmMPKl/pDEST™27.

Transfection o f Freestyle 293-F cells with BmMPKl/pDEST™27 Expression Vectors
The expression vectors, BmMPKl/pDEST™27, were transfected and the
expression of BmMPKl was evaluated in FreeStyle™ 293-F cells (Invitrogen). These
cells are established from primary embryonal human kidney cells and were used due to
their high transfection efficiency as well as high level recombinant protein production

(19). Cells were maintained in 125 mL polycarbonate Erlenmeyer flask containing pre
warmed serum-free Freestyle 293 expression medium (Invitrogen). The flask was placed
on an orbital shaker platform rotating at 135 rpm in a 37°C humidified incubator with 8%
C 0 2. These cells were subcultured every 3-4 days when the cell density reached between
2-3 x 106 viable cells / mL with the cell viability greater than 90%. The cell density and
the viability of cells were determined by counting the cells with hemocytometer using the
tryphan blue exclusion method (20). Live cells exclude the typhan blue dye as oppose to
dead cells which take up the dye. After the cells were passaged three times, an aliquot of
cells were frozen at a density of 5-8 x 106 viable cells / mL in freezing medium composed
of 90% Fresstyle 293 expression medium and 10% sterile dimethyl sulfoxide (DMSO).
These cells were immediately placed in liquid nitrogen for future use.
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The day before transfection, cells were passaged at 7 x 105 cells / mL. On the day
of transfection, the cells were diluted to 1 x 106 cells / mL if the cell viability was greater
than 90 %. In order to transfect the mammalian expression vectors, 30 pg o f each plasmid
(pDEST™26 and pDEST™27) were diluted with Opti-MEM I in a final volume o f 1 mL.
Next, 60 pL of FreeStyle™ 293fectin reagent (Invitrogen) was diluted with Opti-MEM I
in a total volume of 1 mL, mixed gently and incubated at room temperature for 5 minutes.
The 293fectin reagent is a cationic lipid-based transfection reagent which is a proprietary
formulation for highly efficient transfection of the plasmid DNA (20). After 5 minutes,
the diluted DNA was added to the diluted 293fectin reagent, gently mixed, and incubated
for 25 minutes at room temperature to allow DNA-293fectin complex to form. After 25
minutes, the DNA-293fectin complex is added to a flask containing pre-warmed media
with cells diluted to 1 x 106 cells / mL. The flask is then placed in a 37°C humidified
incubator on an orbital shaker platform rotating at 135 rpm with 8% C 0 2. Also, a
negative control flask was prepared containing 2 ml o f Opti-MEM I instead o f the DNA293fectin complex. After transfection, the cells were incubated for 48 hours without
media change as per manufacturer’s instructions. A second transfection reagent,
FreeStyle™ MAX reagent (Invitrogen), was also used in some experiments as per
manufacturer’s instructions (Invitrogen) (21).

After 48 hours, some cells were treated with 400 pM sodium arsenate for 3 hours.
This treatment has been shown to activate stress kinase pathway in mammalian cells and
lead to the isolation of fully active p38 without the necessity o f using recombinant
upstream activating kinase (5). Cell lysates were prepared at 4°C. Tranfected cells were
centrifuged at 100 x g for 5 minutes at 4°C. Cells were washed with lOmL o f pre-chilled
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IX PBS and centrifuged again at 100 x g for 5 minutes at 4°C. Cells were lysed with
appropriate buffers on ice for 15 minutes with 2 mL o f pre-chilled lysis buffer added for
every 50-100 x 106 cells. After the incubation, cell lysates were centrifuges at 14,000 x g
for 10 minutes at 4°C to pellet the nuclei. A 50 pL aliquot was saved and stored at -20°C
for future use.
The

lysis

buffer

BmMPKl/pDEST™ 27,

for

cells

consisted

of:

transfected
10

mM

with

HEPES

GST
pH

7.4,

fusion
50

vector,
mM

|3-

glycerolphosphate, 1% Triton X-100, 10% glycerol, 2 mM EDTA, 2 mM ethlyene glycol
tetraacetic acid (EGTA), 1 mM dithiothreitol (DTT), 10 mM NaF and 1:100 protease
inhibitor (Sigma-Aldrich). The cell lysate preparation protocol was later modified to
using a commercial mammalian protein extraction reagent (M-PER, Thermo- Fisher
Scientific).
Negative control lysates from cells transfected with pDEST™27 without the
BmMPKl insert were prepared in the corresponding buffers. These lysates served as
negative controls for BmMPKl expression.

Purification o f GST-tagged BmMPKl
Purification of GST-tagged BmM PKl, inactive and activated fractions, was
conducted using high affinity GST column resin (GenScript) as per manufacturer’s
instructions (22). Cell lysate was incubated for 1 hour in the high affinity GST column
resin to allow protein binding to the column. The column was washed with 2 mL o f IX
PBS four times with an absorbance reading at 280 nm taken after each wash. The column
was then washed once with 2 ml of elution buffer without 10 mM reduced L-glutathione
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containing: 25 mM HEPES, 150 mM NaCl, 1 mM DTT, 10% glycerol, 0.1 mM EDTA,
1:100 Halts protease inhibitor (Thermo-Scientific), and 10 mM reduced L-glutathione
(added during elution). Protein was eluted with elution buffer containing lOmM reduced
L-glutathione. 5 bed volumes of elution buffer were used with 10 minute incubation
during each elution.
The fractions were analyzed for protein using the Bradford assay (Sigma-Aldrich,
(25). The standard for the assays was bovine serum albumin (BSA). The fractions were
diluted in IX PBS. The assay was conducted in a half volume 96-well plate (Coming) by
adding equal volumes of the samples (standard and inactive and active BmM PKl) and
Bradford reagent. The absorbance was measured at 595 nm using Synergy 2 microplate
reader. The amount of protein obtained from the inactive and active GST-tagged
BmMPKl fractions are shown in Table 1.

SDS-PAGE and Western Blotting o f BmMPKl protein
BmMPKl

protein samples were analyzed using sodium dodecyl sulfate

polyacrilamide gel electrophoresis (SDS-PAGE). Samples were prepared in NuPAGE
SDS sample buffer (Invitrogen) containing NuPAGE reducing agent and placed in a
heating block at 90°C for 5 minutes. The samples were loaded on a 10-well NuPAGE 412% Bis-Tris gel (Invitrogen) and were mn at 200V for 40 minutes using MOPS SDS
running buffer (Invitrogen). Novex sharp pre-stained protein standards (Invitrogen) were
loaded on the gel as molecular weight markers. After 40 minutes, the gel was stained for
1 hour with staining solution containing: 0.05% Coomassie Blue, 10% acetic Acid and

14

44% Methanol. Gels were fixed in 50% methanol and 10% acetic acid for 30 minutes and
destained in 5% acetic acid for 1 hour. The gel was photographed and evaluated.
For Western Blotting, proteins were electrotransferred from SDS-PAGE on to
polyvinylidene fluoride (PVDF) membrane in transfer buffer using a TE77XP semi-dry
blotter (Hoefer) at 54 mA for 1 hour per blot. The membranes were then incubated in
blocking solution (5% non-fat dry milk) for 1 hour.

After 1 hour, the membranes

containing inactive BmMPKl protein was incubated in anti-GST goat polyclonal IgG
antibody (GE Healthcare) for 1 hour. The primary antibody was prepared in 10 mL of
Tris buffered saline with Tween 20 (TBST) with the following: 1:1000 dilution o f AntiGST goat polyclonal IgG antibody, 10 mg o f BSA, and 0.01% sodium azide. The
membranes were washed 3 times with TBST with 5 minute incubations during the
washes. After washing, the membrane was incubated with alkaline phosphatase (AP)
linked mouse anti-goat IgG (1:5000 in 10 mL o f TBST, Santa Cruz Biotechnology)
secondary antibody for 1 hour.

The western blot was developed with 2 mL of

Chromogenic Western Blue® Stabilized Substrate for AP (Promega) and analyzed.
The Western blot of stress activated (sodium arsenate) BmMPKl protein was
developed as outlined earlier with the following changes: primary antibody, phospho-p38
rabbit polyclonal IgG antibody (1:100, Santa Cruz Biotechnologies); and the secondary
antibody, alkaline phosphatase linked anti-rabbit IgG (1:7500, Promega). Both the
primary and secondary antibodies were prepared as stated earlier.

Activity o/B m M PK l kinase activity
/. [y-32p]ATP assay
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32

[y- p]ATP assay was used to determine the activity o f the BmMPKl enzyme.
Radioactively labeled adenosine-5'-triphosphate [y-32p]ATP (PerkinElmer) was used. The
BmMPKl activity was determined by the incorporation o f the radioactive phosphate into
BmMPKl itself through auto-phosphorylation and into myelin basic protein (MBP).
MBP is a protein substrate that most MAPK phosphorylate (24). MBP was incubated in
presence and absence of BmMPKl and the p38 inhibitors BIRB796, and RWJ67657.
The total assay volume was 20 pL containing the following: 15 mM HEPES, pH 7.4, 25
mM B-glycerolphosphate, 15 mM NaCl, 10 mM MgCl2, 1 mM EGTA, and 0.02% Tween
20, 1.0 pg of substrate (MBP) in the absence and presence o f 0.64 pg o f enzyme
(BmM PKl) and p38 inhibitors (1 pM and 10 pM). All o f the inhibitors were prepared in
DMSO. The samples were prepared and pre-incubated at 37°C for 10 minutes.
The reaction was initiated with 4 pL o f 250 pM ATP solution containing 0.4
pCi/pL [y-32p]ATP to each samples and incubated at 37°C for 20 minutes. After 20
minutes, the reaction was terminated with NuPAGE SDS sample buffer (Invitrogen)
containing NuPAGE reducing agent (Invitrogen). An SDS-PAGE was performed and
stained as stated earlier. The gel was dried onto blotting paper (Sigma-Aldrich) using an
Ephortec gel dryer. The dried gel was exposed to Kodak Biomax Maximum Resolution
film in the dark room for 5 hours. The film was developed in the dark room by placing
the film in developer solution (Sigma-Aldrich) at room temperature for 5 minutes. The
film was washed with water for 30 seconds and placed in fixer solution (Sigma-Aldrich)
at room temperature for 1 minute. It was then washed with water for 2-3 seconds and
allowed to dry. The film was photographed and analyzed using Image J program (25)
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where the area under the curve (AUC) for the scanned lanes was determined to calculate
the pixel intensity of the bands.

II. IMAP assay
Enzyme kinetics and inhibitor screening was conducted using an Immobilized
metal ion affinity-based fluorescence polarization (IMAP) assay (Molecular Devices).
IMAP is a high-throughput fluorescent based assay suitable for high-throughput
screening. The assay is initiated with the incubation of enzyme and ATP with fluorescent
peptide substrate producing phophorylated fluorescent peptide product. The assay is
terminated by the addition of a nanoparticle suspension containing a coupled trivalent
metal ion (Mm) which binds the phosphorylated peptide product. As a result o f binding,
there is a slower rotation speed of peptide product in turn increasing the Fluorescence
polarization (FP) signal (26).
The IMAP assay was conducted as per manufacturer’s instructions (Molecular
Devices). The reaction conditions were the following: the enzyme, un-activate and
activated BmM PKl, prepared in 1 mM DTT (Fisher Scientific), 100 pM ATP (SigmaAldrich), IX Reaction Buffer-Tween (RB-T) buffer (Molecular Devices), with the
absence or presence of 1 pL MKK6 (Sigma-Aldrich). The concentration range for the
unactive BmMPKl was 210 ng - 1 ng and the concentration range for the activated
BmMPKl was 400 ng - 6 ng. The reaction was initiated with addition o f 100 nM
fluorescent substrate, FAM-p38tide, prepared in IX RB-T buffer and incubated at room
temperature on a plate shaker (Bamstead/Lab-line) for 1 hour. The assay volume was 20
pL and was conducted in a low volume black 96-well plate (Coming). After the 1 hour
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incubation, the reaction was terminated with the addition o f 60 pL o f PBB containing the
nanoparticles prepared as per manufacturer’s instructions (Molecular Devices) and
incubated on a plate shaker for 1 hour. After 1 hour, the plate was read using Synergy 2
microplate reader. The plate was using an excitation wavelength o f 485 nm and an
emission wavelength of 528 nm (26). The plate consisted o f background containing
substrate and ATP. The data was analyzed in Microsoft Excel, and was corrected for
background.
Another IMAP assay was conducted with the use of different p38 inhibitors on
activated BmMPKl and human p38. The p38 inhibitors used were BIRB796 (Axon),
RWJ67657 was synthesized at Montclair State University by Dr. Fina Liotta’s laboratory
and SB203580 (Selleck). The assay was conducted as stated earlier however with the
following assay conditions: 160 ng o f activated BmMPKl and 50 ng o f p38 were
prepared in 1 mM DTT, 100 pM ATP, IX RB-Tween buffer, and water. The inhibitors
were added to the prepared enzyme and p38 covering 25,000 nM - 3 nM concentration
ranges. The plate consisted of background containing substrate and ATP, blank
containing the buffer only, and the maximal containing enzyme, activated BmMPKl and
p38, substrate and ATP. The reaction was initiated with addition o f 200 nM fluorescent
substrate, FAM-p38tide, prepared in IX RB-Tween buffer and incubated at room
temperature on a titer plate shaker for 1 hour. After 1 hour, the progressive binding buffer
was added and the plate was read as stated earlier. The data was analyzed in Microsoft
Excel and corrected for background. The percent inhibition was calculated and the data
was fit using four parameter logistic curve with solver in Microsoft excel.
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Effect o f p38 inhibitors on B. malayi
I. B. malayi Culture, p38 Inhibitor Treatment and Phenotypic Analysis
Female adult B. Malayi parasites, harvested from infected jirds (small rodents),
were procured from the NIAID/NIH Filariasis Research Reagent Resource Center (FR3).
Adult worms were plated in 24 well plates with 2 mL o f Advanced RPMI 1640 media
supplemented with 25 mM HEPES, L-Glutamine, Penicillin-Streptomycin, Amphotericin
B solution, 5% heat inactivated fetal bovine serum and placed in a 37°C humidified
incubator with 5% CO 2 . After 24 hours, the adult worms were selected based upon
motility and microfilaria release. Parasite motility was given a score from 0-4 with 0, no
motility (dead); 1, very little movement (twitch-like movements); 2, appreciable motility;
3, moderate motility; and 4, highly active.
Microfilariae release was scored as follows: (-) no microfilariae, (+/-) some
microfilariae, (+) moderate levels o f microfilariae, (++) and (+++) if the parasite secrets
quantities of microfilariae. After the parasites were scored, six worms were pre-selected
for each group based on motility and microfilariae release and were transferred to new
plates. Inhibitor treatment groups received the p38 inhibitors, BIRB796 (10 and 20 pM)
and SB203580 (10 and 25 pM), along with a 0.1% DMSO (final concentration in
cultures) vehicle control. p38 inhibitors stock solutions were prepared in 100% DMSO.
Cultures were placed in a 37°C humidified incubator with 5% C 0 2 for 48 hours. The
worms were transferred into a new plate containing fresh media and drug every 48 hours.
After the worms were transferred into fresh media, the amount o f secreted microfilariae
in the media was determined every 48 hours and analyzed by a one sided unpaired
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Student-t test using Microsoft Excel. The motility o f the worms were observed every 24
hours and analyzed by a one sided unpaired Student-t test using Microsoft Excel.

II. Assessment o f BIRB796 in Arsenate-Induced Stress Responses in B.malayi
In C. elegans, PMK-1 (a p38 ortholog/ BmMPKl ortholog), has been shown to be
activated by oxidative stress (27, 28). In order to determine if BmMPKl is involved in

B.malayi stress pathway, worms were stressed with 5 mM sodium arsenate with / without
10 pM BIRB796 as stated earlier. Worm motility was observed every 24 hours and
scored as previously described. A one sided unpaired Student-t test was calculated using
Microsoft Excel.

I ll Microfilariae counts
After the worms were transferred into fresh media, the levels o f secreted
microfilariae in the media were determined. Media containing microfilariae was
centrifuged at 5000 x g for 5 minutes to pellet the microfilariae and the pellet
resuspended in 100 pL of media. The sample was loaded into a hemocytometer and
microfilariae was counted and analyzed.
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Results

Expression and purification o f recombinant BmMPKl
BmMPKl kinase, the B.malayi filarial parasite ortholog o f human p38 and

C.elegans PMK-1/2, was successfully expressed in human Freestyle HEK 293-F cells
using the Gateway cloning technology (Invitrogen). As previously mentioned, the
Gateway technology allows efficient transfer o f the a gene into multiple vectors using in

vitro recombination. Several attempts were made using the Gateway system to express
recombinant BmMPKl in bacterial (E . coli) and mammalian (Freestyle HEK 293-F)
cells. Efficient expression was only obtained in Freestyle 293-F cells using the
pDEST™27 expression vectors which produced a GST-tagged recombinant protein.

Freestyle HEK 293-F cells were transfected with the BmM PKl/pDEST™ 27
plasmid and cultured for 48 hours. The cells were harvested and recombinant BmMPKl
purified using a glutathione affinity column (materials and method). The analysis of
column fractions using SDS-PAGE and Western blotting revealed successful expression
and purification of GST-tagged BmMPKl from Freestyle HEK 293-F cells (Figure 4).
The purification procedure gave a preparation which was approximately 80 - 90% pure
(Figure 4, lane 7 & 8). Western blot analysis revealed a band at a molecular weight o f 67
kDa, the expected molecular weight o f a BmMPKl (41 kDa) and GST (26 kDa) fusion
protein (Figure 4B, lanes 7 & 8).

Enzymatic activity o/B m M PK l
Not surprisingly, recombinant BmMPKl purified from HEK 293 F cells does not
exhibit protein kinase activity (Figure 5A) when assayed using the IMAP p38 kinase
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assay (materials & methods). Since human p38 is known to require activation by
upstream kinases it is likely that the same is true for BmM PKl. All isoforms o f human
p38 MAP kinase have been shown to be activated by an upstream activator called MKK6
(7). As stated earlier, the activation o f p38 leads to dual phosphorylation o f both
threonine and tyrosine residues in the T-G-Y motif. Based on the sequence similarity and
highly conserved T-G-Y m otif in BmMPKl when compared to human (Figure 3), we
tested if MKK6 can activate inactive BmM PKl. Pre-incubation o f BmMPKl with active
human MKK6 gave a significant increase in kinase activity as measured by fluorescence
polarization (Figure 5A). Under the conditions o f the assay, kinase activity is dependent
on the concentration of BmMPKl and to be saturated at approximately 200 ng. A
significant decrease in kinase activity was observed when the p38 inhibitor, RWJ67657,
was added to the reaction. These results illustrate the highly conserved nature of
nematode and human p38-type kinases both at the level o f the activation mechanism and
inhibitor action.
It has been previously reported that recombinant human p38 expressed in
mammalian cells can be activated in situ by treatment with sodium arsenate (5). In order
to determine if BmMPKl can be similarly activated, Freestyle 293-F cells were
transfected with BmMPKl/pDEST™ 27 for 48 hours and stressed with 400 pM sodium
arsenate 3 hours prior to harvesting the cells. BmMPKl was purified and kinase activity
was evaluated. Sodium arsenate treatment leads to dramatic activation o f BmMPKl
(Figure 5B). Addition of recombinant MKK6 to the reaction provided an additional, but
small, increase in kinase activity, indicating that sodium arsenate treatment is an effective
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means of activating BmM PKl. Addition of the p38 inhibitor, RWJ 67657, again
effectively inhibits kinase activity (Figure 5B).
In order to

demonstrate that activation o f BmMPKl

is due to

dual

phosphorylation of the T-G-Y- motif, a Western blot was performed using a rabbit
polyclonal antibody that specifically recognizes human T-G-Y-phosphorylated p38.
Analysis of BmMPKl purification fractions from sodium arsenate stressed HEK 293F
cells with the anti-phospho p38 antibody reveals a 67 kDa band (Figure 6A) indicating
that BmMPKl is phosphorylated at the T-G-Y- domain. These results further attest to the
highly conserve nature of this site between human and B. malayi p38 kinases.
The IMAP p38 protein kinase assay used in the previous experiments utilizes a
peptide substrate. In order to establish an assay using a protein substrate, an assay
utilizing radioactively labeled [y-32P]ATP, and the common MAPK substrate, myelin
basic protein (MBP), was established (materials and methods). BmMPKl phosphorylated
MBP as indicated by the incorporation o f [y-32P] into a 20 kDa MBP band observed in
the autoradiogram shown in Figure 7 (lane 3). In addition, a prominent band at 67 kDa
corresponding to auto-phosphorylated BmMPKl was observed (Figure 7, lane 2). Auto
phosphorylation is a common property of most protein kinases. As a control, the substrate
was incubated with ATP in the absence o f BmMPKl and as expected nothing was seen
(Figure 7, lane-1).
The effects of the p38 inhibitors, BIRB796 and RWJ67657, were next examined
on the activity of BmMPKl using [y-32P] ATP and MBP as a substrate.
revealed that the inhibitors inhibited the incorporation o f [y-32P]

This study

into MBP (Figure 8).

BIRB796 decreased the activity of BmMPKl by 94% at 10 pM and 73% at 1 pM, while
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RWJ67657 at 1 pM had comparative inhibition with BIRB796 at 1 pM but at 10 pM
showed only 61% inhibition compared to BIRB796. Additionally, complete inhibition of
BmMPKl autophophorylation was observed by both the inhibitors (Figure 8).
In order to validate the BmMPKl IMAP assay as a potential high throughput drug
screening assay, dose response curves for three p38 inhibitors were determined for
BmMPKl and human p38. Dose response curves were generated for the p38 inhibitors,
SB203580, RWJ67657, and BIRB796. The half maximal inhibitory concentration (IC50)
of the inhibitor was calculated to determine the relative potency o f the compounds. This
study revealed that RWJ67657 is a potent inhibitor for both p38 and BmMPKl except it
is 10 fold less potent against BmMPKl (Figure 9 and table-2). This was also observed
with BIRB796 and SB203580. Even though the p38 inhibitors are 10 fold less potent
with BmM PKl, it needs to be remembered that BmMPKl is a different from human p38.
Nevertheless, p38 inhibitors do inhibit BmMPKl in the sub-micromolar range and may
be a useful starting point for the synthesis o f more potent and selective inhibitors.

Effects o f p38 Inhibitors on B. malayi Parasite motility
As previously shown, potent inhibition o f activated BmMPKl using p38
inhibitors such as RWJ67657, BIRB796, and SB203580 was observed. Based on these
results, we tested if p38 inhibitors would exhibit effects on the parasite B. malayi.
BIRB796, when added to B. malayi cultures, had a dramatic effect on parasite motility at
24, 48, and 72 hours (Figure 10). There was a minimal effect seen with BIRB796 at 10
pM and with SB203580 at 25 and 10 pM. Parasite motility is a validated measure of
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parasite viability (27), therefore p38 inhibitors, especially o f the BIRB796 class, appear
to have potential as anti-parasitic agents.

Effects o f p38 Inhibitors on Microfilariae Secretion
After observing the effect o f p38 inhibitors on the parasite motility, we next tested
if p38 inhibitors had an effect on parasite microfilariae secretion. This study revealed that
BIRB796 at 20 pM significantly decreased the number o f microfilariae secreted by the
parasite when compared to other treatment groups (Figure 11). These results indicate that
p38 inhibitors such as BIRB796, have effects on early stages of the parasite and that
BmMPKl may play an important role in parasite embryogenesis. C. elegans PMK-1 has
been implicated in playing a role in embryogenesis (28, 29).

Effects o f p38 Inhibitors on B. malayi Stress Responses
Prior research has shown that PMK-1/2, p38 ortholog, from C. elegans plays an
important role in protecting the organism from oxidative stress. Elimination o f PMK-1/2
through genetic means, results in the inability o f the worm to respond to oxidative stress,
such as that induced by sodium arsenate (30, 31). Based on these results, we tested if
BmMPKl plays a role in protecting B. malayi from oxidative stress. B. malayi are largely
resistant to oxidative stress induced with 5.0 mM sodium arsenate (Figure 12). However,
addition of a sub-optimal concentration (in terms o f effects on motility) o f BIRB 796 (10
uM) in the presence of sodium arsenate resulted in a significant decrease in parasite
motility 72 hours and within 96 hours, no motility was observed (Figure 12). This also
shows that BmMPKl may be involved in protection o f the organism and that p38
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inhibitor such as BIRB796 can inhibit the activity o f the parasitic enzyme and in turn
decrease the parasite viability.
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Discussion
Lymphatic filariasis is highly disfiguring and debilitating disease caused by
filarial parasites such as B. malayi, for which few effective treatment options exist.
Present treatments are effective against eliminating microfilariae but not in killing adult
worms. Treatment options are needed that kill both the microfilariae and adult worms. I
have studied a B. malayi ortholog o f human p38 MAP kinase, termed BmM PKl, as a
potential drug target for the treatment o f filariasis. Evidence exists demonstrating antiparasitic effects of p38 inhibitors against other parasites such as, T. gondii and E.

multicularis (4, 12). For my thesis research, I have produced recombinant BmM PKl,
demonstrated activation by the human upstream activating enzyme MKK6 and
demonstrated inhibition of active BmMPKl with known p38 kinase inhibitors. Although
the potency o f the p38 inhibitors I evaluated is 10-30 times less against BmMPKl as
compared to human p38, these inhibitors are a good starting point for the synthesis of
more potent and selective BmMPKl inhibitors.
Treatment of B. malayi parasites with p38 inhibitors demonstrated that BmMPKl
plays an important role in parasite viability, embryogenesis and protection o f the parasite
against oxidative stress. One inhibitor in particular, BIRB796, was particularly effective
in inhibiting adult worm motility, microfilariae release and protective responses against
oxidative stress. It is interesting that BIRB796 inhibits all human p38 isoforms while the
other classes (e.g. RWJ67657 and SB203580) only inhibit the a & (3 isoforms. It is quite
possible that BIRB796 inhibits other BmMPKl isoforms in a similar manner and
therefore exhibit more potent effects against the parasite.
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My results indicate that BmMPKl is a viable therapeutic target. In summary, we
have successfully expressed BmMPKl in Freestyle 293-F cells. I have shown BIRJB796,
allosteric p38 inhibitor, has shown an effect on the enzymatic activity o f BmMPKl in

vitro and has an effect on the parasite viability in culture. I have also shown that
BIRB796 has an effect on the parasite viability when stressed with sodium arsenate
revealing a possibility that p38 ortholog maybe involved in protecting the organism.
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Figure 1: Lifecycle of the lymphatic filariasis parasite (B. malayi). According to
centers for disease control, the typical vector for B. wtf/ayzfilariasis are mosquito species
from the genera Mansonia and Aedes. During a blood meal, an infected mosquito
introduces third-stage filarial larvae onto the skin o f the human host, where they penetrate
into the bite wound O . They develop into adults that commonly reside in the lymphatics
O . The adult worms resemble those o f Wuchereria bancrofti but are smaller. Female
worms measure 43 to 55 mm in length by 130 to 170 pm in width, and males measure 13
to 23 mm in length by 70 to 80 pm in width. Adults produce microfilariae, measuring
177 to 230 pm in length and 5 to 7 pm in width, which are sheathed and have nocturnal
periodicity. The microfilariae migrate into lymph and enter the blood stream reaching the
peripheral blood 0 . A mosquito ingests the microfilariae during a blood meal O . After
ingestion, the microfilariae lose their sheaths and work their way through the wall o f the
proventriculus and cardiac portion o f the midgut to reach the thoracic muscles 0 . There
the microfilariae develop into first-stage larvae 0 a n d subsequently into third-stage larvae
0 . The third-stage larvae migrate through the hemocoel to the mosquito's prosbocis Q
and can infect another human when the mosquito takes a blood meal 0 .
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O

Figure 2: Structures of p38 inhibitors. (A) Structure o f diaryl urea based p38 MAP
kinase inhibitor, BIRB796. (B) Structure o f N-substituted Pyrinidylimadazole based p38
MAP kinase inhibitor, RWJ67657. (C) Structure o f Pyrinidylimadazole based p38 MAP
kinase inhibitor, SB203580.
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Figure 3: Clustal W Alignment of human and nematodes, p38 MAP Kinase
Orthologs. In order from top to bottom: BmMPKl form B. malayi, PMK1 (p38 ortholog)
from C. elegans, Human p38 kinase (MAPK14), and EmPK2 (p38 ortholog) from E.
multicularis.
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Sample:

Crude Extract
(Hg/mL)

Flowthrough
Oig/mL)

Washes
(pg/mL)

Elutions
(fig/mL)

Inactive

10,608

6,761.3

99.5

55.6

Activated

5,728

5,435

421.0

10.53

Table-1: Protein Concentration of Inactive vs. Activated fractions of GST-tagged
BmMPKl fractions. BSA was used as standard in a Bradford assay.
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Figure 4: Purification of B. malayi GST-BmMPKl from Freestyle 293-F Cells.
Molecular weight markers (lane 1 & 10), Positive Control - GST p38 (lane 2), GSTBmMPKl - Crude Extract (lane 3), GST-BmMPKl - Flow through (lane-4), GSTBmMPKl - Wash-1 (lane-5), GST-BmMPKl - W ash-2 (lane 6), GST-BmMPKl Eluent-1 (lane 7), GST-BmMPKl - Eluent-2 (lane 8), and GST-BmMPKl - Eluent-3
(lane 9). (A) Coomassie Blue stained 4-12% Bis-Tris gel. (B) Western blot o f GSTBmMPKl developed using anti-GST goat polyclonal IgG antibody.
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Figure 5: Enzymatic activity of unactivated vs. activated BmMPKl using IMAP
assay: Both the unactivated and the activated BmMPKl were expressed in Freestyle 293F cells. The BmMPKl was activated by stressing the Freestyle 293-F cells with 400 pM
sodium arsenate 3 hours prior to harvesting the cells. (A) The blue diamond’s represents
unactivated BmM PKl, and the red squares represent unactivated BmMPKl in the
presence of MKK6. (B) The blue diamond’s represent stress activated (sodium arsenate)
BmMPKl and the red squares represents activated BmMPKl in the presence o f MKK6.
In both A and B, the green triangles and the red circles represent the presence o f 10 pM
RWJ67657, p38 inhibitor. The emission intensity was collected at 528 nm upon
excitation wavelength at 485 nm using Synergy2 (BioTek).
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Figure 6: Dual Phosphorylation of BmMPKl T-G-Y domain by Arsenate-Induced
Oxidative Stress. Molecular weight markers (lane 1), Positive Control - GST p38 (lane
2), activated BmMPKl - Crude Extract (lane 3), activated BmMPKl - Flow through
(lane-4), activated BmMPKl - Eluent-1 (lane-5), activated BmMPKl - Eluent-2 (lane 6),
activated BmMPKl - Eluent-3 (lane 7), activated BmMPKl - Eluent-4 (lane 8),
activated BmMPKl - Eluent-5 (lane 9), and Glutathione Column Resin (lane 10). (A)
Western blot developed with phosphor-p38 Rabbit polyclonal IgG antibody. (B) Western
blot developed with anti-GST goat polyclonal IgG antibody.
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Figure 7: Phosphorylation of MBP by BmMPKl:
[ y - 32p ] A T P and MBP (lane 1), [ y-32p]ATP and BmMPKl (lane 2), and [ y-32p]ATP,
MBP, and BmMPKl (lane 3). Myelin Basic Protein (MBP) was incubated with [ y32p]ATP in the absence and presence of BmMPKl at 37°C for 20 minutes. The reaction
was terminated by the addition of SDS sample buffer. An SDS-PAGE was conducted and
the phosphorylation was detected by autoradiography.
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Figure 8: Inhibition of BmMPKl Myelin Basic Protein phosphorylation with p38
inhibitors. [y-32p]ATP, MBP, and BmMPKl (lane 1), [y-32p]ATP, MBP, BmM PKl, and
BIRB796 1 pM (lane 2), [y-32p]ATP, MBP, BmM PKl, and BIRB796 10 pM (lane 3), [y32p]ATP, MBP, BmM PKl, and RWJ67657 1 uM (lane 4), and [y-32p]ATP, MBP,
BmM PKl, and RWJ67657 10 pM (lane 5). MBP stands for Myelin Basic Protein. MBP
was incubated with [y-32p]ATP in the absence and presence o f BmMPKl at 37°C for 20
minutes. The reaction was terminated by the addition o f SDS sample buffer. (A) An SDSPAGE was conducted and the phosphorylation was detected by Autoradiography. (B)
The bands were scanned in ImageJ program calculating area under the curve (AUC)
determining the pixel intensity.
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Figure 9: Effect of p38 inhibitors on BmMPKl Kinase Activity. (A) Effect of
different concentration o f SB203580, RWJ67657, and BIRB796 on p38. (B) Effect of
different concentration of SB203580, RWJ67657, and BIRB796 on BmM PKl.

38

IC5q(nM)
Compound

p38

BmMPKl

Ratio

SB203580

28.2

249

9

RWJ67657

3.7

133

36

BIRB796
4.2
137
32
Table-2: Comparison of relative potency of 3 p38 inhibitors to p38 and BmMPKl.
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Figure 10: The effect of p38 inhibitors on B. malayi. Adult female worms were pre
selected so that worms secreted the same amount o f microfilariae. The worms were
incubated with BIRB796 (20 & 10 pM) and SB203580 (20 & 10 pM) for 3 days. The
motility of the parasite was observed every 24 hours and a score 0-4 was given. ** p<
0.001, * p < 0.01 by a one sided unpaired Student-t test. N= 5 or 6 worms. Error bars are
1 SD.
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Figure 11: The effect of p38 inhibitors on B. malayi microfilariae secretion. Adult
female worms were pre-selected so that worms secreted similar amount o f microfilariae.
The worms were incubated with BIRB796 (20 & 10 pM) and SB203580 (15 & 30 pM)
for 3 days. The microfilariae secreted by the parasite was counted every 24 hours. ** p <
0.001, by a one sided paired Student-t test. N—3 - 6 worms Error bars are 1 SD.
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Figure 12: The effects of p38 inhibitors B. malayi Responses to Sodium-arsenate
Induced Oxidative Stress. Adult female worms were pre-selected so that worms
secreted similar amount of microfilariae. The worms were incubated with 0.1% DMSO,
sodium arsenate 5 mM, Sodium Arsenate 5 mM with BIRB796 10 pM, and BIRB796 10
pM. for 4 days. The motility o f the parasite was observed every 24 hours and a score 0-4
was given. ** p< 0.001, * p < 0.01 by a two sided unpaired Student-t test N= 5 or 6
worms Error bars are 1 SD
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